GraniteShares 2x Long COIN Daily ETF vs Cassava Sciences Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.44, while Cassava Sciences Inc trades at $1.1 (market cap $52.66M). Which is the better fit depends on your goals.
| CONL | FLNA | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.57 | $4.64 |
52-Week Low | $4.09 | $1.09 |
Market Cap | — | $52.66M |
Enterprise Value | — | -$33.92M |
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 2.02% on the day, reflecting a challenging year-to-date performance. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, with significant losses tied to Coinbase stock swings and leveraged daily resets.
The outlook remains highly speculative, offering potential for explosive gains if Bitcoin rallies but carrying substantial risk from daily leverage decay and Coinbase volatility. Investors face amplified losses in downturns, making this suitable only for short-term traders with high risk tolerance.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →